Literature DB >> 6639003

5-fluorocytosine susceptibility of pathogenic fungi in the presence of allopurinol: potential for improving the therapeutic index of 5-fluorocytosine.

T M Kerkering, P M Schwartz, A Espinel-Ingroff, P J Turek, R B Diasio.   

Abstract

The minimal inhibitory concentration of 5-fluorocytosine in 18 pathogenic fungal isolates was not altered by either allopurinol (100 microM) or oxypurinol (100 microM). Since allopurinol at this level clinically has been demonstrated to interfere with 5-fluorouracil anabolism, thereby reducing toxicity owing to 5-fluorouracil, allopurinol may be useful in counteracting the 5-fluorouracil-induced myelotoxicity observed in patients being treated with 5-fluorocytosine without interfering with the antifungal activity of 5-fluorocytosine.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6639003      PMCID: PMC185345          DOI: 10.1128/AAC.24.3.448

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Allopurinol modification of the toxicity and antitumor activity of 5-fluorouracil.

Authors:  P M Schwartz; J M Dunigan; J C Marsh; R E Handschumacher
Journal:  Cancer Res       Date:  1980-06       Impact factor: 12.701

2.  Metabolic studies with 5-fluorocytosine-6-14C in mouse, rat, rabbit, dog and man.

Authors:  A Polak; E Eschenhof; M Fernex; H J Scholer
Journal:  Chemotherapy       Date:  1976       Impact factor: 2.544

Review 3.  Flucytosine.

Authors:  J E Bennet
Journal:  Ann Intern Med       Date:  1977-03       Impact factor: 25.391

4.  Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans: possible factor in 5-fluorocytosine clinical toxicity.

Authors:  R B Diasio; D E Lakings; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

5.  Bone marrow toxicity associated with 5-fluorocytosine therapy.

Authors:  C A Kauffman; P T Frame
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191

6.  The metabolism of 5-fluorocytosine-2-14-C and of cytosine-14-C in the rat and the disposition of 5-fluorocytosine-2-14-C in man.

Authors:  B A Koechlin; F Rubio; S Palmer; T Gabriel; R Duschinsky
Journal:  Biochem Pharmacol       Date:  1966-04       Impact factor: 5.858

7.  Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients.

Authors:  R E Finch; M R Bending; A F Lant
Journal:  Br J Clin Pharmacol       Date:  1979-06       Impact factor: 4.335

8.  Allopurinol kinetics.

Authors:  K Hande; E Reed; B Chabner
Journal:  Clin Pharmacol Ther       Date:  1978-05       Impact factor: 6.875

9.  Identification of minor metabolites of 5-fluorocytosine in man by chemical ionization gas chromatography mass spectrometry.

Authors:  K M Williams; A M Duffield; R K Christopher; P J Finlayson
Journal:  Biomed Mass Spectrom       Date:  1981-04

10.  Allopurinol modulation of fluorouracil toxicity.

Authors:  R M Fox; R L Woods; M H Tattersall; A A Piper; D Sampson
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.